AsPC-1 Metastatic Tumor Model Service for Pancreas Cancer

The AsPC-1 metastatic tumor model for pancreatic cancer is an aggressive in vivo xenograft platform that reproduces the rapid growth and widespread dissemination characteristic of late-stage pancreatic ductal adenocarcinoma (PDAC). Alfa Cytology provides complete AsPC-1 metastatic model services—including orthotopic, subcutaneous, and systemic dissemination formats—with expert study design, longitudinal monitoring, and detailed endpoint analysis to power your preclinical pancreatic cancer research.

Overview of AsPC-1 Metastatic Tumor Model for Pancreas Cancer

AsPC-1 was established in 1982 from the ascitic fluid of a 62-year-old Caucasian woman with adenocarcinoma of the head of the pancreas that had metastasized to multiple abdominal organs; the culture was noted for abundant mucin and carcinoembryonic antigen (CEA) production, consistent with its poorly differentiated, mucinous phenotype. The line carries the oncogenic KRAS G12D mutation together with alterations in TP53, while reported data for CDKN2A/p16 and SMAD4/DPC4 vary between studies—a reflection of the genetic heterogeneity of the original tumor and potential sub-clonal drift during long-term culture. Molecularly, AsPC-1 closely resembles a major late-stage PDAC subtype, and it is among the most aggressive pancreatic cell lines available, showing acquired resistance to cisplatin and frequent use in gemcitabine-resistance research.

Fig 1. AsPC-1 liver adhesion cluster assay: pre-perfusion input cells (AsPC-1 Ctrl vs DSG2 KO) perfused through the liver, with counting chambers, flow cytometry singlet/doublet/multiplet analysis, and immunostaining (laminin, tumor cells) of liver sections showing DSG2 knockout reduces cluster size and liver seeding efficiency — dissecting the cell-cluster mechanics of AsPC-1 liver metastasis initiation. (Dietrich, Niclas, et al., 2024)

In in vivo work, AsPC-1 displays striking tumorigenic and metastatic behavior. Orthotopic implantation into the pancreatic parenchyma of immunodeficient mice achieves a 100% tumor take rate and triggers rapid local invasion into adjacent organs (including the spleen) together with spontaneous metastatic spread; in direct comparisons, AsPC-1 tumors metastasize more aggressively and shorten survival more markedly than MIA PaCa-2. The line is also widely deployed in experimental metastasis formats: intravenous (tail vein) injection seeds pulmonary colonies, intracardiac injection models widespread organ colonization, and intraperitoneal inoculation mimics peritoneal carcinomatosis. When stably labeled with luciferase or fluorescent reporters, AsPC-1 tumors can be tracked non-invasively by in vivo imaging, and endpoint analysis—spanning metastatic nodule counts, H&E histopathology, and immunohistochemistry—makes the model a rigorous benchmark for evaluating KRAS-targeted agents, chemotherapy combinations, and anti-metastatic strategies in pancreatic cancer.

Cell Line Information: AsPC-1

Key attributes of the AsPC-1 cell line relevant to metastatic model studies are summarized below.

Our Services

Specializing in hard-to-model gastrointestinal malignancies, Alfa Cytology delivers end-to-end AsPC-1 metastatic tumor model services, from cell authentication and reporter engineering to orthotopic or systemic inoculation, in vivo imaging, therapeutic intervention, and exhaustive metastatic endpoint characterization. Our pancreatic cancer team tailors each study to your compound's mechanism, whether you are profiling KRAS G12D inhibitors, testing chemotherapy backbones, or interrogating resistance pathways.

Workflow of AsPC-1 Metastatic Tumor Model Construction

Establishing a robust AsPC-1 metastatic model demands meticulous control from cell preparation through final analysis. The workflow below outlines the standard process.

1. Cell line authentication and preparation: AsPC-1 cells are identity-confirmed by STR profiling, verified mycoplasma-negative, and expanded under standardized conditions to ensure consistent viability and aggressive growth at inoculation.
2. Reporter labeling (optional): Where longitudinal tracking is required, cells are stably transduced with luciferase or fluorescent reporters and validated for signal stability before animal use.
3. Model format and route selection: The study design defines the format—orthotopic implantation into the pancreatic parenchyma for spontaneous metastasis, subcutaneous engraftment for primary tumor pharmacology, or tail vein/intracardiac/intraperitoneal delivery for experimental dissemination—with matched immunodeficient hosts (nude, NOD/SCID, or NSG mice).
4. Mouse preparation and inoculation: Mice are acclimated and randomized; AsPC-1 cells (commonly 1×10⁶ to 5×10⁶ cells, resuspended in PBS or medium/Matrigel mixes depending on the route) are implanted under sterile, ethically approved surgical conditions.
5. Tumor and metastasis monitoring: Primary tumor volume, body weight, and clinical status are recorded on schedule, while metastatic burden is tracked by in vivo bioluminescence or fluorescence imaging in reporter-labeled studies.
6. Treatment administration: When tumors reach predefined volumes or imaging signals plateau, animals are randomized to treatment arms and dosed with KRAS inhibitors, chemotherapies, targeted agents, or combinations per the study plan.
7. Endpoint analysis: At the study endpoint, pancreas, lungs, liver, spleen, lymph nodes, and peritoneum are examined; metastatic lesions are counted, and tissues are processed for H&E histopathology, immunohistochemistry, and molecular analyses.
8. Data analysis and reporting: Tumor growth curves, imaging time courses, metastasis counts, and survival data are analyzed statistically and compiled into a comprehensive report supporting candidate progression decisions.

Fig 2. AsPC-1 Metastatic Tumor Model construction workflow.

Case Study-AsPC-1 Metastatic Tumor Model Development

Alfa Cytology has built and applied AsPC-1 metastatic tumor models across a range of preclinical pancreatic cancer programs. These models have served to evaluate candidate agents against primary tumor growth and metastatic spread, to benchmark regimens against standard chemotherapy references, and to investigate treatment-resistance questions under controlled in vivo conditions. Representative case information and study datasets can be shared with clients upon request, with study parameters adjustable to the specific objectives of each program.

Why Choose Alfa Cytology?

Alfa Cytology brings focused expertise in aggressive pancreatic cancer modeling to every AsPC-1 metastatic study. Clients partner with us for the following reasons:

• Demonstrated proficiency with aggressive PDAC models, including orthotopic AsPC-1 platforms with validated metastatic behavior.
• Multiple engraftment routes—orthotopic, subcutaneous, tail vein, intracardiac, and intraperitoneal—matched to distinct scientific questions.
• Optional luciferase or fluorescent labeling for non-invasive in vivo tracking of primary tumors and metastases.
• Strict STR authentication and mycoplasma testing to safeguard data integrity.
• Flexible treatment arms, survival endpoints, and multi-organ histopathology tailored to each study.
• Responsive project management and delivery of clear, decision-ready reports on agreed timelines.

Contact Us

If your pancreatic cancer program needs a metastatic model with genuine aggressive behavior, our team is ready to help. Contact us to explore study design options for the AsPC-1 metastatic tumor model, and reach out today to put Alfa Cytology behind your next preclinical milestone.

For research use only. Not intended for any clinical use.